1
Paul J Carter, Leonard G Presta: Humanized antibodies and methods for making them. Genentech, Wendy M Lee, April 25, 2000: US06054297 (468 worldwide citation)

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.


2
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Idec Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, April 7, 1998: US05736137 (387 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


3
Cabilly Shmuel, Holmes William Evans, Wetzel Ronald Burnell, Heyneker Herbert Louis, Riggs Arthur Dale: Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor.. Genentech, Hope City, November 14, 1984: EP0125023-A1 (379 worldwide citation)

Recombinant DNA techniques are used to produce both immunoglobulins which are analogous to those normally found in vertebrate systems and to take advantage of these gene modification techniques to construct chimeric or other modified forms.


4
Randy R Robinson, Alvin Y Liu, Jeffrey A Ledbetter: Chimeric antibody with specificity to human B cell surface antigen. XOMA Corporation, Sterne Kessler Goldstein & Fox, March 19, 1996: US05500362 (339 worldwide citation)

The present invention relates to a chimeric IgG1 antibody molecule comprising two heavy chains and two light chains, each of the chains comprising a human constant region and a variable region, said antibody having specificity for the antigen bound by the 2H7 murine monoclonal antibody. The inventio ...


5
Taniguchi Masaru, Kurosawa Yoshikazu Lions Mansi, Sugita Kou Zou: Process for the production of a chimera monoclonal antibody.. Japan Res Dev, February 19, 1986: EP0171496-A2 (327 worldwide citation)

This invention concerns a animal-human chimera monoclonal antibody whose side-effects such as anaphylaxis and serum sickness are thought to be greatly reduced when it is administered to man. The chimera monoclonal antibody consists of a variable region derived from experimental animals and a constan ...


6
Bosslet Klaus Dr, Hermentin Peter Dr, Seemann Gerhard Dr, Kuhlmann Ludwig Dr, Steinstraesser Axel Dr Dr: Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof.. Behringwerke, December 27, 1990: EP0404097-A2 (298 worldwide citation)

The invention relates to bispecific and oligospecific, mono- and oligovalent receptors which are prepared by genetic manipulation by fusion of DNA coding for F(ab) fragments of the antibodies of two or more different specificities, using suitable linkers. Preferably one of these specificities is dir ...


7

8
Hanai Nobuo, Nakamura Kazuyasu, Shoji Emi, Yamasaki Motoo, Uchida Kazuhisa, Shinkawa Toyohide, Imabeppu Susumu, Kanda Yutaka, Yamane Naoko, Anazawa Hideharu: Method for controlling the activity of immunologically functional molecule. Kyowa Hakko Kogyo, January 30, 2002: EP1176195-A1 (258 worldwide citation)

The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promote ...


9
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, July 7, 1998: US05776456 (187 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


10
Man Sung Co, David A Scheinberg, Cary L Queen: Antibodies with increased binding affinity. Protein Design Labs, Memorial Sloan Kettering Cancer Center, Townsend & Townsend & Crew, February 26, 2002: US06350861 (176 worldwide citation)

The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region a ...